Biologic Therapy for Psoriasis: Cutting Edge Treatment Principles

ISBN-13: 9783030929404 / Angielski / Miękka / 2023 / 146 str.

Nicholas Brownstone; Tina Bhutani; Wilson Liao

Opis

Biologic therapy is a treatment that strives to modulate a patient's immune system to fight a given disease. In psoriasis, a skin disorder that is partly caused by a dysregulated immune system resulting in well-demarcated red areas of the skin with white scales, biologic therapy has the potential to vastly improve upon patient outcomes by minimizing the symptoms of this disease while maximizing the safety profile of the therapy.   This book offers an up-to-date and comprehensive review on biologic therapy for the treatment of psoriasis. With over 10 FDA approved biologic agents for psoriasis (with more in the pipeline), confusion exists among providers regarding which agent is best for a particular patient. Chapters cover all FDA approved psoriasis biologic agents (including pipeline agents) for use in pediatric, adult, and geriatric patients. This book is unique in that it will not only cover cutting edge treatment principles based on the latest research, it will also be one of the most comprehensive reviews of psoriasis biologics in the COVID-19 era.   Biologic Therapy for Psoriasis is a must-have resource for board certified dermatologists and rheumatologists, dermatology and rheumatology residents and fellows, dermatology physician assistants, nurse practitioners and medical students. The ultimate goal of this book is to improve patient care by making the busy practicing dermatology provider more adept with these particular therapies.

Spis treści

Table of Contents

 

Chapter 1: Introduction to Biologic Therapy for Psoriasis

●     Review epidemiology, morphology and types of psoriasis

●     Review immune-mediated pathophysiology of psoriasis

●     Introduce and review psoriasis outcome measures

●     Briefly mention and discuss older systemic agents (methotrexate, cyclosporine and acitretin) and the advantages/disadvantages versus biologic agents

 

Chapter 2: Laboratory Monitoring: TB, Hepatitis and HIV

●     Discuss risk of TB activation, role of TB testing and treatment of latent TB infections

●     Discuss risk of Hep B/C reactivation, role of testing and treatment regimen for Hep B/C infections and management of positive Hep B Core Ab

●     Discuss role of HIV screening in biologic therapy for psoriasis

 

 

Chapter 3: TNF-alpha class of Biologic Agents in Psoriatic Disease

●     Review up do date safety and efficacy data from phase III clinical trials for certolizumab, adalimumab, etanercept in psoriasis

●     Review up do date safety and efficacy data from phase III clinical trials for certolizumab, adalimumab, golimumab, etanercept in psoriasis in psoriatic arthritis

●     Discuss the unique merits and demerits for each agent

 

Chapter 4: IL-17 class of Biologic Agents in Psoriatic Disease

●     Review up do date safety and efficacy data from phase III clinical trials for secukinumab, brodalumab and ixekizumab in psoriasis

●     Review up do date safety and efficacy data from phase III clinical trials for secukinumab,  and ixekizumab in psoriasis in psoriatic arthritis

●     Discuss the unique merits and demerits for each agent

●     Include phase II data for pipeline agents

Chapter 5: IL-12/23 and IL-23 class of Biologic Agents in Psoriatic Disease

●     Review up do date safety and efficacy data from phase III clinical trials for ustekinumab, guselkumab, risankizumab and tildrakizumab in psoriasis

●     Review up do date safety and efficacy data from phase III clinical trials for ustekinumab and guselkumab in psoriatic arthritis

●     Discuss the unique merits and demerits for each agent

●     Include phase II date for pipeline agents

 

Chapter 6: Combination Therapy with Biologic Agents

●     Review available safety and efficacy data with biologic agents and systemic agents (methotrexate, cyclosporine, acitretin, and other biologics (dual biologics))

●     Review available safety and efficacy data with biologic agents and phototherapy

●     Review available safety and efficacy data with biologic agents apremilast

 

 

Chapter 7: Biologic Agents in the Treatment of Pediatric Psoriasis

●     Review effective counseling methods for parents

●     Review data on compliance with biologic use in the pediatric population along with different types of delivery methods (ex. auto-injector vs. syringe)

●     Discuss unique challenges and solutions when using a biologic agents in the pediatric population

●     Review phase III safety and efficacy data for ustekinumab, etanercept and ixekizumab for use in the pediatric population

●     Discuss the role of biologic agents in the treatment of recalcitrant cases of pediatric psoriasis

 

 

Chapter 8: Special Site Psoriasis 

·         Review safety and efficacy data for biologic treatment of nail psoriasis

·         Review safety and efficacy data for biologic treatment of scalp psoriasis

·         Review safety and efficacy data for biologic treatment of palmoplantar psoriasis

·         Review safety and efficacy data for biologic treatment of genital and inverse psoriasis

 

Chapter 9: Comparing Biologic Agents in the Treatment of Psoriasis

●     Introduce concept of network meta-analysis

●     Review key network meta-analysis studies for psoriasis biologics including

○     Short term and long term efficacy of biologic agents

○     Cumulative clinical improvement and speed of improvement with biologic agents

○     Efficacy and safety of biologic agents

○     Tolerability

●     Discuss data on cost-effectiveness of different biologic treatments for psoriasis (economic model of analysis)

●     Discuss data and review studies on drug survivability

 

Chapter 10: Long Term Registry Data for Psoriasis Biologics

●     Discuss importance of registry studies and how they are conducted

●     Discuss benefits and disadvantages or registry studies

●     Review key findings from psoriasis registry studies concerning biologic agents (examples PSOLAR, BADBIR, Psonet initiative)

●     Discuss real world efficacy studies for psoriasis biologics

 

 

Chapter 11: Psoriasis Biologic Agents in Special Populations

·         Discuss biologic use in pregnant and breastfeeding patients

·         Discuss biologic use in patients who are HIV positive

·         Discuss biologic use in patients with history of malignancy

·         Discuss biologic use in geriatric patients

·         Discuss management recommendation for biologic use in patients undergoing surgery

·         Discuss the role of biomarkers/precision medicine with psoriasis biologics

 

Chapter 12: Psoriasis Biologics and the COVID-19 Pandemic: Lessons Learned

●     Discuss data on COVID-19 infection risk and psoriasis biologics

●     Discuss data on COVID-19 morbidity and psoriasis biologics

●     Discuss role of psoriasis biologics in treating cytokine storm

●     Discuss data on covid-19 vaccination responses in patients receiving biologics

●     Discuss lessons learned and implications for future novel viral outbreaks

 

 

 

 

 

 

 

O autorze

Nicholas Brownstone 

University of California, San Francisco 

Psoriasis and Skin Treatment Center 

San Francisco 

California 

USA

 

Tina Bhutani 

University of California, San Francisco 

Psoriasis and Skin Treatment Center 

San Francisco 

California 

USA 

Wilson Liao 

University of California, San Francisco 

Psoriasis and Skin Treatment Center 

San Francisco 

California 

USA